Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. - Test2 - elhamkhani - TriplyDB

Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.

Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.

http://www.wikidata.org/entity/Q33803829

about

Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses Angiotensin receptor blockers: are they related to lung cancer?Angiotensin receptor blockers and risk of prostate cancer among United States veterans Renin-angiotensin system blockade: Its contribution and controversy What is good for the circulation also lessens cancer risk Rediscovering ACE: novel insights into the many roles of the angiotensin-converting enzyme Review article: the pathophysiological roles of the renin-angiotensin system in the gastrointestinal tract Repurposing of approved cardiovascular drugs Lack of an association between angiotensin receptor blocker based therapy and increased risk of cancer: evidence from large observational studies Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database Renin-angiotensin system blockade for the risk of cancer and death.A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors On Inference for Kendall's τ within a Longitudinal Data Setting Does outcome reporting bias "cause" cancer? Risks associated with hidden data on Angiotensin receptor blockers.Long-term use of angiotensin receptor blockers and the risk of cancer A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2.Nonexperimental comparative effectiveness research using linked healthcare databases Transcriptome-based analysis of kidney gene expression changes associated with diabetes in OVE26 mice, in the presence and absence of losartan treatment Sunitinib combined with angiotensin-2 type-1 receptor antagonists induces more necrosis: a murine xenograft model of renal cell carcinoma.GPCRs and cancer Effects of Baicalin on Blood Pressure and Left Ventricular Remodeling in Rats with Renovascular Hypertension Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies.Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information.Clinically relevant doses of candesartan inhibit growth of prostate tumor xenografts in vivo through modulation of tumor angiogenesis Pathophysiologic therapeutic targets in hypertension: a cardiological point of view.Angiotensin II facilitates breast cancer cell migration and metastasis Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine.Effect of RAAS inhibition on the incidence of cancer and cancer mortality in patients with glomerulonephritis.A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial.Clinical utility of valsartan in the treatment of hypertension in children and adolescents The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.Differential effects of enalapril and losartan on body composition and indices of muscle quality in aged male Fischer 344 × Brown Norway rats.G-protein coupled receptors of the renin-angiotensin system: new targets against breast cancer?Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts Preventing the aortic complications of Marfan syndrome: a case-example of translational genomic medicine Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk A Novel Cellular Model to Study Angiotensin II AT2 Receptor Function in Breast Cancer Cells Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy and colorectal cancer: a systematic review and meta-analysis.Prognonstic impact of renin-angiotensin system blockade in localised upper-tract urothelial carcinoma

P2860

Q24289205-D3ED1F00-E9EA-4BD7-8A8C-825ABCA574AD Q24622669-42D3F04C-819A-4E52-8B63-FE5D30FFAB6B Q24626548-D0AD7B0F-0BA4-4DE4-B7ED-C38E80FB20B7 Q26827221-811161CA-5DEF-4BF0-9D4E-76AE1555E5D3 Q26859261-F43B9FFE-9024-4DCF-BADD-2C71C71CD2F0 Q27004277-32547146-09BD-4A28-BB52-19C9C6A2341E Q27009109-CE1793AB-DAC6-4B99-9B9D-74BE3BFA61E7 Q28074453-A8CE9712-9F1E-4DF7-9289-65D815461E90 Q28544725-00722C84-E136-4847-AF52-607E2E0FE9B3 Q28730234-246D8299-08DC-4060-92F0-6B42C4D0A4A4 Q30249043-ACE43998-5D9C-462C-9DCD-ED05D904001F Q30432209-006D8B71-E571-4FF9-9AB0-99C7CA23E586 Q30538154-AF583A3D-B6C3-486E-9A71-5B5CAFB1537B Q30576331-303E0632-6069-40EF-9CF7-B5BA93C46E82 Q31109379-04E68337-9712-4BE7-9A5D-4B66D463EF87 Q33407858-AF03089C-16A1-45C2-B1C3-7CBB68ABDC1E Q33576469-3C2A0659-909B-405C-A1F4-D92219774655 Q33610151-0774F99F-73C3-4D0C-8659-8BFBD35EE62A Q33745382-9B8B4C3E-9553-4E52-8034-8B84D33E0991 Q33828719-21C3C712-873C-4E9C-8C12-C52B4C625E02 Q33834911-E863E058-183F-421A-A4B6-FA98FB8B76AA Q34005101-AEB32FCF-3227-47B9-8C85-AA425BC189E5 Q34093100-52C92DA7-C32B-40DF-9D54-8503C804040A Q34125083-0EB110FA-800F-4B03-862C-8706553DA303 Q34142036-720D5A1A-8F55-4B58-8381-C4F7F04E72E9 Q34247434-164BAE5E-7C79-4753-A7F7-E8CB09A455B1 Q34363486-177B7662-4E8A-4A6C-9B75-26202D2E0A52 Q34451915-F6213A7F-45A2-497A-B5D1-9BC5C0BD7ADF Q34668757-E8351848-11B5-411A-A127-46FE9C5A291C Q34957546-1A7A8F9A-7608-4202-B55C-553404BBCA80 Q35001942-9E73ABA7-B7C0-44B1-A8D8-C394866DD4DF Q35080208-D774080A-12AE-4B39-87C0-CC210278D763 Q35089791-648D8B6A-F1AD-4349-9F10-9D7C4104E002 Q35093193-E8DBE0D8-3403-4B6B-B71F-8FA26C6272DD Q35120570-104AD3B6-6144-446F-B39B-AC9B3728FD71 Q35131970-4A19EC40-D844-4DDE-A337-92D99653D4DA Q35539305-28074F61-A5D9-4816-B5F1-31DDC4F73BC4 Q35609097-B01E710E-C354-4B1A-9581-4DD0803CA018 Q35665360-B2966154-D779-46A4-8ED6-2A9778635F00 Q35681985-7128819C-F0B3-45E7-A8BC-9F53BE39EBBA

P2860

Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.

http://www.wikidata.org/entity/Q33803829

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Angiotensin-receptor blockade ...... randomised controlled trials.

@ast

Angiotensin-receptor blockade ...... randomised controlled trials.

@en

type

label

Angiotensin-receptor blockade ...... randomised controlled trials.

@ast

Angiotensin-receptor blockade ...... randomised controlled trials.

@en

prefLabel

Angiotensin-receptor blockade ...... randomised controlled trials.

@ast

Angiotensin-receptor blockade ...... randomised controlled trials.

@en

P1433

Q33803829-0B579CEB-BF92-4D0F-8F11-E78CCE2F3D72

P1476

Q33803829-FF59011A-44DB-4B99-A331-AD7594CECA75

P2093

Q33803829-1B213E12-CA8E-4B34-B70B-27BE9BA1FAC1

Q33803829-74913CF0-5C28-4F17-B8BF-65AE67D387F6

Q33803829-7C459A2E-EC75-4937-9974-C8FF03017AF4

Q33803829-9E5582CC-C075-404F-90C2-2F1863B4AE88

Q33803829-A4E6FD1F-EC45-4C39-8CED-F3C02C146790

P2860

Q33803829-0081E22E-8C8C-4BB3-9431-07C5F5580096

Q33803829-180C4741-A3B5-4C64-B693-28588BE0252A

Q33803829-19740457-FE43-4F79-BF5E-FE427915D1E8

Q33803829-24184868-E40D-4509-AC6D-0DD25C75CB78

Q33803829-2485FB67-61B6-4B4C-A6B3-B512977A894D

Q33803829-271FC473-3A08-4933-A651-ABC1A73A3704

Q33803829-4A7AEB2E-6A70-4CBE-8E35-E86E5329F50A

Q33803829-4AB11D9F-FC0A-4694-A629-BA3B0D1CDD00

Q33803829-5310A063-18A0-4265-A866-948A369EC35D

Q33803829-5384E8BC-1CB7-4183-8259-913D45300E94

P304

Q33803829-8E4BCF8F-AF86-4DB0-AD49-B541BEAE4C39

P31

Q33803829-AC6756A4-1627-4142-8B06-6B1F68312349

Q33803829-c7ac7c59-7cf2-4e25-afc5-4c77b601d4ee

P356

Q33803829-9AFAA5C4-FAB5-48D4-993B-A9F1B67728B7

P433

Q33803829-66BA8E74-6D1E-4CAC-B4AB-E14E2D911F5C

P478

Q33803829-2898EE7D-BCB2-4336-8053-68A680CADF10

P577

Q33803829-19E6B3B7-4598-4850-911E-97F087A5B3C8

P5875

Q33803829-F4AF857F-8992-4B33-B5C5-E66B2446FFDE

P698

Q33803829-186C61F8-8EFF-4588-BAFE-CA190AD97BED

P921

Q33803829-368DF113-1F9A-4FA7-AB2D-0A3C4F9FAF5A

P932

Q33803829-D5DDC5D5-ED35-4CA8-8624-A462607C887C

P356

S1470-2045(10)70106-6

P1433

The Lancet Oncology

P1476

Angiotensin-receptor blockade ...... randomised controlled trials.

@en

P2093

Daniel I Simon

http://www.w3.org/2001/XMLSchema#string

Douglas Y Rowland

http://www.w3.org/2001/XMLSchema#string

Ilke Sipahi

http://www.w3.org/2001/XMLSchema#string

James C Fang

http://www.w3.org/2001/XMLSchema#string

Sara M Debanne

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 G

Meta-analysis, Simpson's paradox, and the number needed to treat

Operating characteristics of a rank correlation test for publication bias

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Telmisartan, ramipril, or both in patients at high risk for vascular events.

Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading

P304

627-636

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(10)70106-6

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44667841

http://www.w3.org/2001/XMLSchema#string

P698

20542468

http://www.w3.org/2001/XMLSchema#string

P921

P932

4070221

http://www.w3.org/2001/XMLSchema#string